EXCLUSIVE: MyMD Pharmaceuticals Chief Scientific Officer, Dr. Adam Kaplin, M.D., Ph.D. Now Interviewing On Benzinga’s Power Hour Show
Click To Tune In Here...https://www.youtube.com/watch?v=77132igq94c
MyMD Pharmaceuticals Announces Data It Says Demonstrates 8,000 Times Higher Potency Of Novel Synthetic Supera-CBD Over Plant-Derived CBD; Shares Move Higher
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating
MyMD Pharmaceuticals Announces Data It Says Demonstrates 8,000 Times Higher Potency Of Novel Synthetic Supera-CBD Over Plant-Derived CBD; Shares Move Higher
MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation Of Phase 2 Clinical Trial Of MYMD-1 For Extending Healthy Lifespan
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate
MyMD Pharmaceuticals Granted U.S. Patent Titled ‘Method of treating disorders associated with chronic inflammation’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6593&f=G&l=50&d=PTXT&p=132&S1=20210824&OS=20210824&RS=20210824
85 Biggest Movers From Yesterday
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
MyMD Pharma Reports US Patent Issued For Co.’s ‘Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases’
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing To Commence Clinical Trials For Oral COVID-19 Vaccine
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic
MyMD Pharmaceuticals Granted U.S. Patent Titled ‘Synthetic cannabinoid compounds for treatment of substance addiction and other disorders’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=(mymd+AND+pharmaceuticals)&OS=mymd+AND+pharmaceutical
MyMD Pharmaceuticals Shares Spike On Volume, Co. Issued Patent Titled ‘METHOD OF TREATING DISORDERS ASSOCIATED WITH CHRONIC INFLAMMATION’
https://patentcenter.uspto.gov/#!/applications/17084012/ifw/docs